| September 2010 | ||||||
|---|---|---|---|---|---|---|
| S | M | T | W | T | F | S |
| 1 | 2 | 3 | 4 | |||
| 5 | 6 | 7 | 8 | 9 | 10 | 11 |
| 12 | 13 | 14 | 15 | 16 | 17 | 18 |
| 19 | 20 | 21 | 22 | 23 | 24 | 25 |
| 26 | 27 | 28 | 29 | 30 | ||
Monthly Archives
June 2010
May 2010
April 2010
March 2010
February 2010
January 2010
December 2009
October 2009
September 2009
August 2009
July 2009
June 2009
May 2009
April 2009
March 2009
February 2009
January 2009
December 2008
October 2008
September 2008
August 2008
July 2008
June 2008
April 2008
Complete Archives
Most recent entries
SpectraScience Provides Corporate Update and Outlook
SpectraScience appoints Sheldon L. Miller Esq. to its Board of Directors
SpectraScience Receives Notification of Pending Issuance of Two Patents
SpectraScience Retains Quorum Consulting
SpectraScience to Exhibit at Digestive Disease Week in New Orleans
SpectraScience Has Second Unannounced Inspection by FDA
SpectraScience’s Jim Hitchin Featured in MDDI Magazine Article
Health Radio - Interview with CEO, Jim Hichin
Professor Andreas Stallmach Chooses WavSTAT(R) Optical Biopsy System for Early Cancer Detection
SpectraScience CEO Jim Hitchin Speaks to Blogtalkradio About Better Cancer Screening Diagnostics
SpectraScience, Inc. Selects CWR & Partners as Its Public Relations Agency of Record
SpectraScience Forms Advisory Board - Governor Tommy Thompson to be Chairman
SpectraScience Releases Shareholder Newsletter
SpectraScience Engages European Contract Research Organization to Manage Clinical Trials
SpectraScience Awarded Japanese Patent 4361683 for Its Optical Biopsy Forceps System
News
SpectraScience Retains Quorum Consulting
May 05, 2010
SAN DIEGO, CA -- SpectraScience, Inc. (OTC.BB:SCIE), a San Diegobased medical device company, announced today that it has retained SanFrancisco based Quorum Consulting to assist in the proper design of current andfuture clinical trials.
Jim Hitchin, SpectraScience CEO, stated,"Safety and effectiveness are no longer the only standards to measureproduct potential. Third-party payers and governmental agencies in the US,Europe, and Asia also want to know the impact of new technologies on budgetsand patient outcomes outside of the clinical trials. Quorum's health economicsand outcomes group supplement our R&D activities by designing, operating,and publishing studies to demonstrate benefits that are of the greatestinterest to our customers."
"Also, obtaining coverage andreimbursement for our new technology requires an innovative strategic plan andtactical expertise. Quorum will help us determine whether existing billingcodes are appropriate for our products. They will evaluate whether coverage isavailable and how studies should be designed to minimize coverage barriers. In addition,they will determine the exact reimbursement amount paid to hospitals,physicians, and work to change payment rates if reimbursement is notadequate."
SpectraScience holds approximately 60 patentsworldwide that have been issued or are pending on its WavSTAT® Optical BiopsySystem and LUMA® Cervical Imaging Systems. These devices are used to assesstissue quickly to help determine if it is normal, pre-cancerous, or cancerous.The WavSTAT and LUMA Systems are approved by the FDA for detecting pre-cancerousand cancerous tissue in the colon and cervix, respectively. An evaluation ofthe WavSTAT for detection of pre-cancers in the throat ("Barrett'sesophagus") is being tested.
Forward-Looking Statements
This news release contains forward-lookingstatements within the meaning of Section 27A of the Securities Act of 1933, asamended, and Section 21E of the Securities Exchange Act of 1934, as amended.These forward-looking statements involve risks and uncertainties that may causeSpectraScience's actual results to differ materially from results discussed inforward-looking statements. Readers are urged to carefully review and considerthe various disclosures made by SpectraScience in this news release, its mostrecent Form 10-K and in SpectraScience's other reports filed with theSecurities and Exchange Commission ("SEC") that attempt to adviseinterested parties of the risks and factors that may affect SpectraScience'sbusiness. These forward-looking statements are qualified in their entirety bythe cautions and risk factors filed by SpectraScience in its annual report onForm 10-K and other documents.
About SpectraScience, Inc.
SpectraScience is a San Diego based medicaldevice company that designs, develops, manufactures and marketsspectrophotometry systems capable of determining whether tissue is normal,pre-cancerous or cancerous without physically removing tissue from the body.The WavSTAT Optical Biopsy System uses light to optically scan tissue andprovide the physician with an immediate analysis. With FDA approval for sale inthe U.S. and the CE Mark for the European Union, the WavSTAT System is thefirst commercially available product that incorporates this innovativetechnology for clinical use. The Company's LUMA imaging technology has receivedFDA approval for an optical non-invasive system that is proven to moreeffectively detect cervical cancer precursors than conventional methodsavailable in the market today.
Contact:
SpectraScience, Inc.
Jim Hitchin
Chief Executive Officer
(858) 847-0200 x201
Hayden Communications
Investor Relations
Todd Pitcher
(858)-518-1387